UA138709U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography, and additionally determine in the patient's serum polymorphism of the methylenetetrahydrofolate reductase gene (MTHFR C677T), the content of endothelin, C-terminal propeptide of collagen type I (-ISIN), protein (PSA), homocysteine and homozygous carrier 677-TT and endothelin levels> 10 ng / ml, SISR <102 ng / ml, IL-6> 10 ng / l, PSA> 6 mg / l, homocysteine> 20 μmol / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, examination of biopsies of the synovial membrane, synovial fluid, cartilage biopsy TSA.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis at an early stage.

According to the useful model, in addition to clinical examination and radiography, the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV C6771T), the content of endothelin, C-terminal propeptide of type I collagen (SICP), interleukin b (IL-6), C-reactive protein (SRP), homocysteine and with homozygous carrier 677-TT, endothelin content 210 ng/ml, SISR "102 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, homocysteine 220 μmol/l are predicted development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, an X-ray is taken, and the MTNEV C677T gene polymorphism is determined. The content of endothelin, SISR, IL-6, SRP, and homocysteine is determined by the immunoenzymatic method. With homozygous carrier 677-TT, levels of endothelin 210 ng/ml, SISR "102 ng/ml, IL-6 "10 ng/l, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.

A specific example of using the method.

Patient V., 65 years old, was hospitalized in the clinic due to pain syndrome in the right hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphism of MTNEV C677T gene was determined in blood serum. The content of endothelin, SISR, IL-6, SRP, homocysteine was determined by immunoenzymatic method. Homozygous carrier 677-TT was established. Levels of endothelin - 24 ng/ml, SISR - 72 ng/ml, IL-6-25 ng/l, SRP - 18 mg/l, homocysteine - μmol/l. The development of osteoarthritis was diagnosed. After 13 months on x-rays

Osteoarthritis was detected.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA The method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that the polymorphism of the methylenetetrahydrofolate reductase gene (MTNEV Сб677Т), the content of endothelin, the C-terminal propeptide of collagen type I (SICP), interleukin 6 (IL- 6), C-reactive protein (SRP), homocysteine and with homozygous carrier 677-171 and endothelin levels 210 ng/ml, SISR "102 ng/ml, IL-b6 210 ng/l, SRP "6 mg/l, homocysteine 220 μmol/l predict the development of osteoarthritis.